PI3K-IN-16

CAS No. 1895876-81-9

PI3K-IN-16( —— )

Catalog No. M12977 CAS No. 1895876-81-9

PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PI3K-IN-16
  • Note
    Research use only, not for human use.
  • Brief Description
    PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor.
  • Description
    PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor with cell IC50 of 12 nM (in PTEN null MDA-MB-468 cell) and 47 nM (in Jeko-1 B-cell), respectively; exhibits no significant activity on PI3Kα; shows profound pharmacodynamic modulation of AKT phosphorylation, excellent tumour growth inhibition in a mouse PTEN-deficient PC3 prostate tumour xenograft.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3K
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1895876-81-9
  • Formula Weight
    467.497
  • Molecular Formula
    C25H26FN3O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    8-((8-fluoro-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)methyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Barlaam B, et al. Bioorg Med Chem Lett. 2016 May 1;26(9):2318-23.
molnova catalog
related products
  • Tenalisib (RP6530)

    Tenalisib shows selectivity over PI3K α (>300-fold) and β (>100-fold) isoforms. Tenalisib exhibits modest proliferation inhibition in both HEL-RS and HEL-RR cells.

  • PI3K/mTOR Inhibitor-...

    PI3K/mTOR Inhibitor-2 is a potent pan inhibitor of PI3K and mTOR with IC50s of 3.4, 34, 16,1 and 4.7 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR. PI3K/mTOR Inhibitor-2 has antitumor activity.

  • GDC-0980

    GDC-0980 (Apitolisib, GNE 390, RG 7422) is a potent, selective, orally available class I PI3K/mTOR inhibitor with IC50 of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, inhibits mTOR inhibitor with Ki of 17 nM.